Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Health (NASDAQ:COSM) has announced a significant expansion of its Sky Premium Life nutraceutical brand with the addition of 60 new SKUs, bringing the total product count to over 150. The expansion supports the brand's global growth through new distribution agreements across multiple territories, including presence in pharmacies and international retail chains like Holland & Barrett, as well as e-commerce platforms like Amazon.

The company's R&D department has developed several new products, including:

• Kakadu Plum with high vitamin C concentration
• Good Morning & Good Night energy and sleep formulations
• ZenBlend for relaxation and sleep
• Skinovate for skin rejuvenation
• Electrolytes in cherry and lemon flavors

Cosmos Health (NASDAQ:COSM) has announced it will not proceed with its planned offering under Form S-1 until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The company, which operates as a diversified healthcare group focusing on pharmaceutical and nutraceutical brands, manufacturing, distribution, and telehealth services, has postponed any potential offering until after the annual financial reporting is complete.

Cosmos Health (NASDAQ:COSM) announced entering the final development phase of CCX0722, its weight management solution. The company is finalizing scale-up production and engaging with Contract Research Organizations (CROs) to complete the technical dossier. Clinical trials are expected to complete between late 2025 and early 2026, with product launch targeted for Q1 or Q2 2026.

The product is seeking potential classification as a Class III medical device. The company aims to enter the global weight management market, valued at $142.58 billion in 2022 with an expected CAGR of 9.7% from 2023 to 2030. CCX0722 is described as a biocompatible hydrogel solution targeting the growing obesity epidemic.

Cosmos Health (NASDAQ:COSM) has filed two new patent applications for innovative cancer treatments using AI-driven drug repurposing. The first patent (N2039647) targets glioma, an aggressive brain cancer, while the second (N2039645) focuses on hematologic malignancies, including multiple myeloma.

The developments stem from the company's collaboration with Cloudpharm and the National Hellenic Research Foundation, utilizing their AI-powered Cloudscreen platform. Recent in vitro studies have validated the therapeutic potential of a repurposed marketed drug for both indications.

The global market outlook is promising, with the glioma treatment market valued at $3.58 billion in 2024, projected to reach $5.1 billion by 2032 (5.20% CAGR). The hematologic malignancies treatment market was valued at $22.23 billion in 2022, expected to reach $41.7 billion by 2032 (6.5% CAGR).

Cosmos Health (NASDAQ:COSM) has appointed Dimitris Moraitis as Vice President of Strategy & Operations. Moraitis brings over 25 years of experience in strategic planning, operations, and business development within the pharmaceutical sector. He has previously held leadership positions at major pharmaceutical companies including DEMO, MENARINI, VIANEX Group, and TIKUN OLAM Europe.

Moraitis has also served as a leader and board member of several prominent pharmaceutical associations, including AESGP (Association of the European Self-Care Industry), EfEX (Hellenic Association of Self-Care Products), SEPTEDE (Association of Enterprises for Infant Nutrition & Special Dietary Products of Greece), and SAFFE (Hellenic Association of Pharmaceutical Enterprises & Representatives).

Cosmos Health (NASDAQ:COSM) has announced that its subsidiary, Cana Laboratories, has secured a new 10-year contract manufacturing agreement with Provident Pharmaceuticals to produce four pharmaceutical products. The agreement covers the production of 8 million packs over the contract period, consisting of:

- Miorelique® (Baclofen oral solution): 200,000 packs annually
- BE Union F.C. (Vitamin B-complex tablets): 400,000 packs annually
- Certorun (Sertraline capsules) in 50mg and 100mg: 200,000 combined packs annually

Cana Laboratories currently operates with two shifts and has the capacity to expand to three shifts to meet increased demand. The products are generic versions of established medications Lioresal, Neurobion, and Zoloft, respectively.

Cosmos Health (NASDAQ:COSM) has received an initial purchase order worth $578,460 from Al Rabwa International Services and Trading for its Sky Premium Life® food supplement products in Qatar. The order encompasses 35 of the Company's 79 SKUs, with Al Rabwa receiving exclusivity rights for distribution.

Al Rabwa, established in 2013, has grown into a leading distribution company in Qatar, serving retail, food service, and wholesale sectors. The company maintains a broad product portfolio supported by global suppliers and producers, along with professional sales, marketing, and customer service operations.

Cosmos Health (NASDAQ:COSM) has filed a patent application (N2039644) for a multiple sclerosis (MS) treatment, leveraging its AI-powered Cloudscreen drug repurposing platform. The initiative stems from the company's collaboration with Cloudpharm and the National Hellenic Research Foundation, supported by NLO's pharma patent experts.

The patent application is based on data-driven in silico evidence and simulations, along with experimental validation, identifying a unique mechanism of action in a repurposed marketed drug for MS treatment. This development targets the growing MS market, which was valued at $25.94 billion in 2023 and is expected to grow at a 5.9% CAGR from 2024 to 2030.

Multiple sclerosis, affecting 2.9 million people globally as of 2023, is a chronic autoimmune disorder impacting the central nervous system. The global market growth is driven by therapeutic advancements, increased healthcare investments, and ongoing research addressing unmet patient needs.

Cosmos Health (NASDAQ:COSM) has secured a €2.2 million (approximately $2.29 million) bond loan through its subsidiary CosmoFarm from a European bank. The loan, announced on January 27, 2025, will be issued in two tranches: €700,000 in Series A Bonds and €1.5 million in Series B Bonds.

The bond loan, maturing on January 27, 2030, carries an interest rate of 2.95% plus the 6-month Euribor rate, payable semi-annually. Series A Bonds will be repaid in 10 equal semi-annual installments, while Series B Bonds are due at maturity. The loan is secured by CosmoFarm's building and includes an option to upsize for additional capital.

The proceeds will support strategic growth initiatives and provide working capital as the company aims to achieve positive operating cash flow.